The DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.
Lactobacillus acidophilus DDS-1 and Bifidobacterium lactis UABla-12 Improve Abdominal Pain Severity and Symptomology in Irritable Bowel Syndrome: Randomized Controlled Trial
Open accessAbstract
This randomized, double-blind, placebo-controlled, multi-center study investigated the clinical efficacy of two probiotic strains on abdominal pain severity and symptomology in irritable bowel syndrome (IBS). Three hundred and thirty adults, aged 18 to 70 years, with IBS according to Rome IV criteria were allocated (1:1:1) to receive placebo, Lactobacillus acidophilus DDS-1 (1 × 1010 CFU/day) or Bifidobacterium animalis subsp. lactis UABla-12 (1 × 1010 CFU/day) over six weeks. The primary outcome was the change in Abdominal Pain Severity - Numeric Rating Scale (APS-NRS). Over the intervention period, APS-NRS was significantly improved in both probiotic groups vs. placebo in absolute terms (DDS-1: −2.59 ± 2.07, p = 0.001; UABla-12: −1.56 ± 1.83, p = 0.001) and in percentage of significant responders (DDS-1: 52.3%, p < 0.001); UABla-12 (28.2%, p = 0.031). Significant amelioration vs. placebo was observed in IBS Symptom Severity Scale (IBS-SSS) scores for L. acidophilus DDS-1 (−133.4 ± 95.19, p < 0.001) and B. lactis UABla-12 (−104.5 ± 96.08, p < 0.001) groups, including sub-scores related to abdominal pain, abdominal distension, bowel habits and quality of life. Additionally, a significant normalization was observed in stool consistency in both probiotic groups over time and as compared to placebo. In conclusion, L. acidophilus DDS-1 and B. lactis UABla-12 improved abdominal pain and symptom severity scores with a corresponding normalization of bowel habits in adults with IBS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hill (2014) · doi:10.1038/nrgastro.2014.66 · Cited by 9,592
(1988) · Cited by 4,111
FRANCIS, C. Y., MORRIS, J., & WHORWELL, P. J. (1997) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1997.142318000.x · Cited by 1,708 · cited 8×
“IBS symptom severity was assessed via the IBS Symptom Severity Scale (IBS-SSS) [23].”
MethodInfluentialActivation of the mucosal immune system in irritable bowel syndrome
Chadwick, V. S., Chen, W., Shu, D., Paulus, B., Bethwaite, P., Tie, A., & Wilson, I. (2002) · Gastroenterology · doi:10.1053/gast.2002.33579 · Cited by 833 · cited 1×
“There is evidence of an activation of the intestinal immune system in IBS resulting in inflammation, including augmented mucosal intraepithelial lymphocytes and mast cells [42,43].”
BackgroundLactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors
Rousseaux, C., Thuru, X., Gelot, A., Barnich, N., Neut, C., Dubuquoy, L., Dubuquoy, C., Merour, E., Geboes, K., Chamaillard, M., et al. (2007) · Nature Medicine · doi:10.1038/nm1521 · Cited by 793 · cited 1×
“acidophilus has been shown to normalize visceral pain responses via induced expression of opioid and cannabinoid receptors in the gut [45].”
BackgroundSelf-citationPatrick, D. L., Drossman, D. A., Frederick, I. O., Dicesare, J., & Puder, K. L. (1998) · Digestive Diseases and Sciences · doi:10.1023/a:1018831127942 · Cited by 761 · cited 1×
“IBS-related quality of life (QoL) was assessed via the IBS-QoL, a 34-item questionnaire with each item rated on a 5-point scale (range: 34–170), with increasing scores indicating deteriorating quality of life [25].”
MethodLiang, P., Liu, S., Xu, F., Jiang, S., Yan, J., He, Q., Liu, W., Lin, C., Zheng, F., Wang, X., et al. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00001 · Cited by 669
Ford, A. C., Moayyedi, P., Lacy, B. E., Lembo, A. J., Saito, Y. A., Schiller, L. R., Soffer, E. E., Spiegel, B. M. R., & Quigley, E. M. M. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.187 · Cited by 645 · cited 2×
“controlled trials with a dichotomous outcome enrolling a total of 4403 participants [7,11].”
BackgroundFord, A. C., Harris, L. A., Lacy, B. E., Quigley, E. M. M., & Moayyedi, P. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15001 · Cited by 619 · cited 1×
“controlled trials with a dichotomous outcome enrolling a total of 4403 participants [7,11].”
BackgroundPathophysiology of irritable bowel syndrome
Holtmann, G. J., Ford, A. C., & Talley, N. J. (2016) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(16)30023-1 · Cited by 590 · cited 1×
“Irritable bowel syndrome (IBS), a functional disorder of the gastrointestinal tract, is characterized by chronic or recurrent abdominal pain and altered bowel habits [1].”
Background
Research works printed but not linked: 1
- Nagala, 2011, Clinical Case Study—Multispecies probiotic supplement minimizes symptoms of irritable bowel syndrome, US Gastroenterol. Hepatol. Rev., 7, 1
Cited by
British Society of Gastroenterology guidelines on the management of irritable bowel syndrome
Vasant, D. H., Paine, P. A., Black, C. J., Houghton, L. A., Everitt, H. A., Corsetti, M., Agrawal, A., Aziz, I., Farmer, A. D., Eugenicos, M. P., et al. (2021) · Gut · doi:10.1136/gutjnl-2021-324598 · Cited by 592
Rastogi, S., & Singh, A. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1042189 · Cited by 326
Lactobacillus and intestinal diseases: Mechanisms of action and clinical applications
Huang, R., Wu, F., Zhou, Q., Wei, W., Yue, J., Xiao, B., & Luo, Z. (2022) · Microbiological Research · doi:10.1016/j.micres.2022.127019 · Cited by 250
Abouelela, M. E., & Helmy, Y. A. (2024) · Microorganisms · doi:10.3390/microorganisms12030430 · Cited by 238
“Those who supplemented with L. acidophilus DDS-1 and B. lactis UABla-12 also witnessed a normalization of stool patterns and experienced enhanced relief from abdominal pain throughout the intervention period [94].”
BackgroundWorld Gastroenterology Organisation Global Guidelines: Probiotics and Prebiotics
Guarner, F., Sanders, M. E., Szajewska, H., Cohen, H., Eliakim, R., Herrera-deGuise, C., Karakan, T., Merenstein, D., Piscoya, A., Ramakrishna, B., et al. (2024) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000002002 · Cited by 209
Metadata
- Authors
- Martoni, C. J., Srivastava, S., & Leyer, G. J.
- Affiliations
- UAS Laboratories LLC, 4375 Duraform Lane, Windsor, WI 53598, USA
- Vedic Lifesciences (India) (IN)
- Corresponding author
- Leyer, Gregory J.
- Venue
- Nutrients
- Publisher
- MDPI AG
- Published
- 2020-01-30
- Volume
- 12
- Issue
- 2
- Pages
- 363
- ISSN
- 2072-6643 (ISSN-L)
- PMC
- PMC7071206
- OpenAlex
- W3004290421
- Cited by
- 123
- References
- 50
- Citations by year
- 2026: 13 · 2025: 24 · 2024: 25 · 2023: 22 · 2022: 25 · 2021: 8 · 2020: 6
- FWCI
- 13.25
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Nutrients (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Keywords
- irritable bowel syndrome, probiotics, abdominal pain, symptom severity, abdominal distension, bowel habits, stool consistency, quality of life, Rome IV criteria
- MeSH terms
- Bifidobacterium animalis, Adolescent, Adult, Aged, Double-Blind Method, Female, Humans, Lactobacillus acidophilus, Male, Middle Aged, Severity of Illness Index, Abdominal Pain, Treatment Outcome, Probiotics, Irritable Bowel Syndrome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lactobacillus acidophilus DDS-1 and Bifidobacterium lactis UABla-12 Improve Abdominal Pain Severity and Symptomology in Irritable Bowel Syndrome: Randomized Controlled Trial. https://app.cochat.ai/papers/10.3390/nu12020363
- The paper
- Martoni, C. J., Srivastava, S., & Leyer, G. J. (2020). Lactobacillus acidophilus DDS-1 and Bifidobacterium lactis UABla-12 Improve Abdominal Pain Severity and Symptomology in Irritable Bowel Syndrome: Randomized Controlled Trial. Nutrients. https://doi.org/10.3390/nu12020363
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.